^
CANCER:

Myelodysplastic Syndrome





Show legend
Group by Gene:
Include preclinical:

0
TGFβ inhibitor
luspatercept-aamt
1
DNA methylation inhibitor
azacitidine
2
DNMT inhibitor
decitabine
3
DNMT inhibitor, Cytidine deaminase inhibitor
decitabine / cedazuridine
4
Bcl2 inhibitor
venetoclax
5
PD1 inhibitor
pembrolizumab
sintilimab
6
CD47 inhibitor
GS-4721
ALX148
7
TIM-3 antagonist
MBG453
8
AXL inhibitor
BGB324
9
XPO1 inhibitor, Nuclear export inhibitor
KPT-8602
10
NEDD8 activating enzyme inhibitor
MLN4924
11
FLT3 inhibitor
quizartinib
12
IDH1 inhibitor
ivosidenib
olutasidenib
13
p53 reactivator
APR-246
14
XPO1 inhibitor
selinexor
15
Glutaminase inhibitor
CB-839
16
Immunomodulator
Orca-T
17
IDH2 inhibitor
enasidenib
18
CDK19 inhibitor, CDK8 inhibitor
RVU120
19
FGFR inhibitor
pemigatinib
20
Topoisomerase II inhibitor, DNMT inhibitor
etoposide IV + decitabine
21
c-KIT-targeted antibody-drug conjugate, RNA polymerase 2 inhibitor
MGTA-117
22
JAK1 inhibitor, JAK2 inhibitor
ruxolitinib
23
TNFα inhibitor, IL-12 inhibitor, IL-6 inhibitor
lenalidomide
24
Thrombopoietin receptor agonist
eltrombopag
25
Retinoic acid receptor agonist, Telomerase inhibitor, DNMT inhibitor, DNA synthesis inhibitor, Cytotoxic T lymphocyte stimulant, DNA-directed DNAP inhibitor
cytarabine + decitabine + tretinoin
26
IRAK-4 inhibitor, FLT3 inhibitor
CA-4948
27
PDGFR inhibitor, Bcr-abl tyrosine kinase inhibitor, c-KIT inhibitor
imatinib
28
PDGFR β inhibitor, PDGFR α inhibitor, FLT3 inhibitor
ARO-002
29
Elongation factor 2 inhibitor, IL-3 antagonist, CD123 inhibitor
tagraxofusp-erzs
30
Elongation factor 2 inhibitor, IL-3 antagonist, CD123 inhibitor, Bcl2 inhibitor
venetoclax + tagraxofusp-erzs
31
DNA methylation inhibitor, Bcl2 inhibitor
venetoclax + azacitidine
32
Topoisomerase II inhibitor, DNA polymerase inhibitor, DNA synthesis inhibitor
cytarabine / daunorubicin liposomal formulation
33
DNA methylation inhibitor, TIM-3 antagonist
azacitidine + MBG453
34
Chemotherapy
VRD
35
IDH1 inhibitor, Bcl2 inhibitor
venetoclax + ivosidenib
36
Hypomethylating agent
Hypomethylating agent
37
TNFα inhibitor, IL-12 inhibitor, DNA methylation inhibitor, IL-6 inhibitor
lenalidomide + azacitidine
38
Multi-tyrosine kinase inhibitor, Bcl2 inhibitor
venetoclax + gilteritinib
39
Immunotherapy
Immunotherapy
40
DNMT inhibitor, TIM-3 antagonist
decitabine + MBG453
41
CDK4 inhibitor, CDK6 inhibitor, CDK9 inhibitor
DSP-2033
42
pan-CLK inhibitor
CTX-712
43
CD33 inhibitor, CD3 agonist, PD1 inhibitor
AMV564 + PD1 inhibitor
No biomarker
TP53 mutation
TP53 wild-type
TP53 R248Q
Chr del(5q) + TP53 expression
TET2 mutation
RUNX1 mutation
ASXL1 mutation
ASXL1 Y588X
Chr del(20q) + ASXL1 deletion
Chr del(20q) + ASXL1 mutation
ASXL1 deletion
ETNK1 mutation
CALR mutation
SRSF2 mutation
NRAS mutation
SETBP1 mutation
CBL mutation
STAT3 mutation
SRSF2 P95L
SRSF2 P95H
FLT3 mutation
IDH1 mutation
SF3B1 mutation
SF3B1 K700E
SF3B1 mutation + Chr del(5q)
DNMT3A mutation
LDHA elevation
TMB-H
U2AF1 mutation
NPM1 mutation
RRM1 underexpression
EZH2 mutation
SLFN11 expression
ANG elevation
AXL elevation
JDP2 overexpression
SPI1 overexpression
IDH2 mutation
FGFR1 rearrangement
WT1 overexpression
KIT positive
miR-192-5p overexpression
BCR-ABL1 fusion
PCM1-PDGFRB fusion
PAN3-PSMA2 fusion
MECOM rearrangement
MECOM mutation + KDM6B mutation
MECOM mutation + KDM6A mutation
PDGFRA rearrangement
BNIP3L elevation
HIF1A overexpression
DDX41 mutation
Chr del(5)(q31)
Chr del(5)(q31.1)
Chr del(5q)
RYBP deletion
ZRSR2 mutation
DNMT3A mutation + SF3B1 mutation
CD33 positive
Chr del(17p)
PIK3CD mutation
AKT3 mutation
PLCG2 mutation
MCL1 expression